Viewing Study NCT07245069

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:56 PM
Ignite Modification Date: 2026-02-02 @ 4:58 AM
Study NCT ID: NCT07245069
Status: RECRUITING
Last Update Posted: 2025-11-24
First Post: 2025-11-17
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Sponsor: University Medical Centre Ljubljana
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Heart Failure View
None Anthracycline-induced Cardiac Toxicity View
None Endothelial Function (FMD) View
None Arterial Stiffness View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Anthracycline-induced cardiac toxicity View
None Dapagliflozin View
None Breast Cancer View
None Cardio-Oncology View
None Primary Prevention View
None Global Longitudinal Strain View
None Myocardial Work View
None Endothelial Function View
None Flow-Mediated Dilation View
None Pulse Wave Velocity View
None Troponin View
None NT-proBNP View
None Heart Failure View
None Inflammation View
None Sodium-Glucose Transporter 2 Inhibitors View